Patients on tirzepatide also experienced more metabolic benefits, such as greater reductions in weight and HbA1c, compared ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

FDA and WHO identified semaglutide suicidal thought reports, exceeding those of other diabetes medications in their adverse ...

These medications have gained popularity due to their effectiveness in promoting weight loss and managing blood sugar levels. However, the TGA's recent updates indicate a troubling association with ...

The Therapeutic Goods Administration issued a new warning for GLP-1 receptor agonists, including Ozempic and Mounjaro, on Monday.

A ustralia's drugs regulator has issued a fresh warning for users of high-profile injectable diabetes and weight-loss drugs such as Ozempic.

1. In this cohort study, dulaglutide, semaglutide, and tirzepatide demonstrated similar risks of gastrointestinal adverse events (AEs) in adults with type 2 diabetes (T2DM). 2. All three agents were ...